Benzinga | Aug 6, 2020 08:20AM EDT

Intellia Therapeutics Q2 EPS $(0.61) Beats $(0.69) Estimate, Sales $16.26M Beat $8.54M Estimate

Intellia Therapeutics (NASDAQ:NTLA) reported quarterly losses of $(0.61) per share which beat the analyst consensus estimate of $(0.69) by 11.59 percent. This is a 8.93 percent decrease over losses of $(0.56) per share from the same period last year. The company reported quarterly sales of $16.26 million which beat the analyst consensus estimate of $8.54 million by 90.43 percent. This is a 46.28 percent increase over sales of $11.12 million the same period last year.